AmDerma & Oculus Enter Multi-Country Agreement

AmDerma Pharmaceuticals, LLC, a privately owned company (and parent company of Quinnova Pharmaceuticals, Inc.) and Oculus Innovative Sciences recently announced the execution of an agreement to develop and commercialize Oculus’ novel proprietary Microcyn Technology drug compounds for major dermatological conditions, including acne. The exclusive agreement includes licensing of the dermatology compounds in the US and India, with a first right of refusal for all member states of the European Union, Canada, Brazil, and Japan. Oculus retains all rights for the rest of the world.

Under the terms of the agreement, Oculus received an undisclosed upfront payment, and will receive multiple clinically based payments upon achievement of several development and regulatory milestones for both acne and secondary indications, as well as future escalating double-digit royalties on net sales of products. The agreement also memorializes the intent for future joint development of additional dermatological products and indications.

“This agreement reflects the AmDerma/Quinnova commitment to the future of dermatology. Microcyn compounds have the potential to bring about significant advancement in the treatment of skin diseases, which affect millions of patients, without adding to the growing problem of antibiotic resistance or steroid overuse,” said Jeffrey Day, Quinnova President. “Our dermatology customers have been pleased with improved patient outcomes as a result of adopting the Microcyn-based compounds for treatment of atopic dermatitis and related skin diseases. We look to build upon this success by growing the family of Microcyn-based dermatology compounds for myriad skin afflictions.”

AmDerma will be responsible for the development costs for the acne formulation as well as other dermatological compounds.

“Oculus is thrilled to expand the scope of our existing partnership with Quinnova and its parent company, AmDerma. Quinnova is doing an exceptional job with the commercial launch of the Atrapro product, and we are confident they are the right partner to commercialize this technology in acne and other dermatological indications,” said Hoji Alimi, Founder and President of Oculus.

AmDerma Pharmaceuticals is a privately held company engaged in the development of pharmaceutical products with dermatological indications. Quinnova Pharmaceuticals, Inc., a wholly owned subsidiary of AmDerma Pharmaceuticals, is a specialty pharmaceutical company founded on innovative, patent-protected dermal delivery technologies. For more information, visit www.quinnova.com.

Oculus Innovative Sciences is a commercial healthcare company that designs, produces, and markets innovative, safe, and effective healthcare products. Oculus is pioneering innovative solutions in multiple markets, including dermatology, oral care, surgical, wound care, animal healthcare and others, and has commercialized products in the US, Europe, India, China, Mexico, and select Middle East countries. For more information, visit www.oculusis.com.